Re: Separation Agreement
IMMUNIC, INC.
August 7, 2026
Daniel Vitt
Email: daniel.vitt@me.com
Re: Separation Agreement
Dear Daniel:
This letter sets forth the terms of the separation agreement (the “Agreement”) which you, Immunic, Inc., a Delaware corporation (the “Company”), and Immunic AG, wholly-owned subsidiary of the Company (the “Company Subsidiary”), have agreed in the context of your employment transition.
1. Separation Date. Subject to the terms and conditions of this Agreement, your employment with the Company will continue through August 7, 2026, which will become your employment termination date (the “Separation Date”).
2. Title. Your title will be changed on the date of this Agreement to Founder and Chair of the Company’s Scientific Advisory Board (the “SAB”). As of the date of this Agreement, you will report to the Chief Executive Officer of the Company (the “CEO”).
3. Service Agreement with the Company Subsidiary. On or prior to the Separation Date, you will enter into an agreement (the “AG Termination Agreement”) with the Company Subsidiary pursuant to which you will cease to be a member of the Executive Board of the Company Subsidiary as of the Separation Date, and your Service Agreement, dated December 18, 2023, with the Company Subsidiary (the “Service Agreement”), will terminate without any ongoing obligations.
…